Business Context and Reporting Period
Company: Manhattan Pharmaceuticals, Inc. (Note: Metadata referenced "TG THERAPEUTICS, INC.", but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Stage: Development stage biopharmaceutical company with no commercial revenues.
Key Activities: The company focuses on developing therapies for underserved populations, including Hedrin (head lice), Topical PTH (1-34) (psoriasis), Altoderm (atopic dermatitis), and Altolyn (mastocytosis). The company voluntarily delisted from the American Stock Exchange (AMEX) in March 2008 and now trades on the OTC Bulletin Board under the symbol "MHAN."
Key Financial Metrics
| Metric | Q3 2008 (3 Months) | YTD 2008 (9 Months) | YTD 2007 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(1,394,316) | $(4,395,877) | $(10,128,078) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.06) | $(0.15) |
| Cash and Cash Equivalents (End of Period) | $35,664 | $35,664 | $2,032,655 (Sep 30, 2007) |
| Working Capital Deficit | $(1,902,540) | $(1,902,540) | $(1,006,124) (Dec 31, 2007) |
| Total Liabilities | $4,962,802 | $4,962,802 | $1,871,662 (Dec 31, 2007) |
| Stockholders' Deficiency | $(4,757,902) | $(4,757,902) | $(891,085) (Dec 31, 2007) |
Debt: As of September 30, 2008, the company held $70,000 in 10% secured notes payable. A significant "Exchange obligation" of $2,949,176 is recorded related to the Hedrin Joint Venture put option.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss for the nine months ended September 30, 2008, decreased by 57% to $4.4 million compared to $10.1 million in the same period in 2007. This was driven primarily by a 75% reduction in Research and Development (R&D) expenses ($1.9M vs $7.4M) due to the discontinuation of certain projects (Oleoyl-estrone and Propofol) and reduced costs for other programs.
- Liquidity Deterioration: Cash and cash equivalents plummeted from $649,686 at December 31, 2007, to $35,664 at September 30, 2008. Net cash used in operating activities was $3.5 million for the nine-month period.
- Liability Increase: Total liabilities increased significantly to $4.96 million, largely due to the recognition of a $2.95 million exchange obligation related to the Hedrin Joint Venture and an increase in accrued expenses.
- Arbitration Award: The company incurred a $646,000 arbitration award from Swiss Pharma in September 2008, of which $542,000 was expensed in the quarter. The company stated it does not have sufficient cash to satisfy this award.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management explicitly states that the company's continued operations depend on raising additional funds. While they believe current resources (including recent financing) will fund operations until mid-2009, there is substantial doubt about the company's ability to continue as a going concern without further equity or debt financing.
- Recent Financing:
- Hedrin JV: Received approximately $3.0 million in cash payments from the Hedrin Joint Venture (Nordic Biotech) during the period.
- 10% Notes: Raised $70,000 in September 2008 via secured promissory notes.
- 12% Notes (Subsequent Event): In November 2008, the company completed the first closing of a $1 million senior secured note offering, realizing $0.8 million in net proceeds.
- Product Development Updates:
- Topical PTH (1-34): Phase 2a clinical study results announced in July 2008 did not demonstrate statistically significant improvement in psoriasis severity compared to placebo, though safety was confirmed. Next steps are under review.
- Hedrin: The FDA directed the product to the Center for Devices and Radiological Health for review as a medical device.
- Risks: Key risks include the inability to secure additional financing, failure of clinical trials, regulatory hurdles, and the inability to satisfy the Swiss Pharma arbitration award.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $35,664 cash balance against the $646,000 Swiss Pharma arbitration award and ongoing operational burn rate.
- Debt Covenants: Review the terms of the 10% and 12% secured notes, including maturity dates and collateral requirements.
- Exchange Obligation: Understand the mechanics of the $2.95 million exchange obligation to Nordic Biotech and the potential dilution impact if the put option is exercised.
- Product Viability: Assess the impact of the negative Phase 2a results for Topical PTH (1-34) on the company's pipeline value and future funding needs.
- Legal Exposure: Confirm the status of the Swiss Pharma arbitration and any potential for further legal action from the former employee regarding patent rights.